Neoplasm Malignant With Kras G12c Mutation clinical trials

Explore recruiting neoplasm malignant with kras g12c mutation clinical trials.

Recruiting neoplasm malignant with kras g12c mutation studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neoplasm Malignant With Kras G12c Mutation trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination with Cetuximab, in Participants with KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)

Norway, Spain, Sweden, Italy, Denmark, France +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Neoplasm Malignant With Kras G12c Mutation trials by city

Neoplasm Malignant With Kras G12c Mutation in Toronto Neoplasm Malignant With Kras G12c Mutation in Vancouver Neoplasm Malignant With Kras G12c Mutation in Montreal Neoplasm Malignant With Kras G12c Mutation in Calgary Neoplasm Malignant With Kras G12c Mutation in Edmonton Neoplasm Malignant With Kras G12c Mutation in Ottawa Neoplasm Malignant With Kras G12c Mutation in Winnipeg Neoplasm Malignant With Kras G12c Mutation in Quebec City Neoplasm Malignant With Kras G12c Mutation in Hamilton Neoplasm Malignant With Kras G12c Mutation in Kitchener Neoplasm Malignant With Kras G12c Mutation in London Neoplasm Malignant With Kras G12c Mutation in Halifax Neoplasm Malignant With Kras G12c Mutation in New York Neoplasm Malignant With Kras G12c Mutation in Los Angeles Neoplasm Malignant With Kras G12c Mutation in Chicago Neoplasm Malignant With Kras G12c Mutation in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease